The two cases progressing to MDS showed DNMT3A and SF3B1 (A4) and TET2 and KRAS (A5) mutations in the first biopsy with acquisition of an additional NRAS mutation in case A5. This evidence concerns the gene KRAS and myelodysplastic syndrome.